Download biomedica product list
Biomedica’s FGF23 ELISA kits now available for the US Biotech community at 25% trial discount.
FGF23 (fibroblast growth factor 23) is a 32 kDa protein with 251 amino acids that is proteolytically processed between arginine179 and serine180 to generate N-terminal and C-terminal fragments. FGF23 is mainly secreted by osteocytes and controls phosphate and 1,25(OH)2 vitamin D homeostasis. Epidemiological data suggest that higher FGF23 concentrations are associated with all-cause mortality, cardiovascular mortality, a higher risk of myocardial infarction, stroke and heart failure.
➡️ Learn more: FGF23 – An Overview
FGF23 ELISA kits available for the US & CA
Biomedica’s FGF23 (intact) and FGF23 (C-terminal) ELISA kits
Biomedica’s FGF23 ELISA kits, widely recognized in Europe and Asia, are now also available in the US.
💡 What makes them a game-changer?
✓ MULTI-MATRIX: for plasma, serum, cell-culture
✓ CONVENIENT: 50 µl sample/well, all buffers included
✓ RELIABLE: validated following quality guidelines
✓ COMPARABLE: good correlation with existing kits
✓ EASY HANDLING: 7 prediluted standards, 2 controls
✓ TRUSTED: cited in more than 80 publications
Biomedica offers world-leading quality products at competitive pricing.
FGF23 ELISA kits available for the US & CA
🚨 Don’t miss out and order your trial kit at 25% discount. Promotion extended until June 30, 2025.
➡️ Contact our US partners or CA partner for your study quote.
Related kits: Sclerostin . OPG . Periostin . Vanin-1 . NT-proBNP . NT-proANP
Literature
Non-Classical Effects of FGF23: Molecular and Clinical Features. Martínez-Heredia L, Canelo-Moreno JM, García-Fontana B, Muñoz-Torres M.Int J Mol Sci. 2024 Apr 30;25(9):4875. doi: 10.3390/ijms25094875. PMID: 38732094; PMCID: PMC11084844.
The role of fibroblast growth factor 23 in regulation of phosphate balance. Wilson R, Mukherjee-Roy N, Gattineni J. Pediatr Nephrol. 2024 Dec;39(12):3439-3451. doi: 10.1007/s00467-024-06395-5. Epub 2024 Jun 14. PMID: 38874635.
FGF23 signalling and physiology. Ho BB, Bergwitz C. J Mol Endocrinol. 2021 Feb;66(2):R23-R32. doi: 10.1530/JME-20-0178. PMID: 33338030; PMCID: PMC8782161.
May is “Osteoporosis Month” raising awareness on bone health. Osteoporosis is estimated to affect 200 million people worldwide. Taking action for prevention, diagnosis and treatment can reduce the risk and the burden of osteoporosis.
Biomedica offers a wide range of bone biomarker ELISA kits for the accurate measurement of FGF23, Sclerostin, Osteoprotegerin, soluble RANKL, DKK-1, IL-6, and others.
Assay Highlights:
• EASY – ready to use calibrators & controls included
• RELIABLE – validated according to international quality guidelines
• WIDELY CITED in 1500 + publications
• COMPETENT CUSTOMER SERVICE
Complete ready-to-use ELISA kits for superior performance and reproducibility: https://buff.ly/2N3xY97
Rafiou Agoro, Pu Ni, Megan L. Noonan, and Kenneth E. White. Front Endocrinol (Lausanne). 2020; 11: 592.
Full publication https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485387/
FGF23 is a phosphaturic hormone derived and secreted primarily by bone osteocytes. Mature, bioactive FGF23 is physiologically designed to target the kidney to regulate phosphate and vitamin D homeostasis; and, in a feedback mechanism to control bone mineralization and FGF23 production.
This review explores the signals involved in the positive and negative regulation of FGF23 in osteocytes, and bridges bone responses with the review of current knowledge on FGF23 endocrine functions in the kidneys.
Check out the Biomedica human FGF23 (C-terminal) and human FGF23 (intact) ELISA kits: https://www.bmgrp.com/shop?category=&type=&reactivity=&s=fgf
- For serum and plasma samples
- Extensively validated according to FDA/ICH/EMEA guidelines
- CE marked – for IVD use in the EU
- Excellent correlation with existing methods
Recent advancements in genetic #research have uncovered new forms of monogenic #osteoporosis. Mutations in WNT1, encoding a WNT/β-catenin pathway ligand WNT1, and PLS3, encoding X chromosomally inherited plastin 3 (PLS3), both result in early-onset osteoporosis with prevalent fractures and disrupted bone metabolism.
Data from a study by Mäkitie RE et al. indicate a link between PLS3 and DKK1 and WNT1 and FGF23 in bone metabolism (measured with biomedica kits). Therefore, DKK1 and FGF23 may be clinically useful biomarkers for PLS3 and WNT1 osteoporosis, respectively.
Check out the Biomedica DKK-1 and FGF23 ELISA kits:
– Reliable – validated according to international guidelines
– Specific – epitope mapped antibodies
– CE marked – widely cited in clinical studies
Biomarkers in WNT1 and PLS3 Osteoporosis: Altered Concentrations of DKK1 and FGF23 . Mäkitie RE et al., J Bone Miner Res, 2020 May;35(5):901-912.
FGF23 (Fibroblast Growth Factor 23), a well-known marker for phosphate metabolism, has achieved independent significance in the cardiovascular system [1]. Several large-scale prospective studies have established FGF23 as an independent risk marker for heart failure and mortality [2,3]. There is also growing evidence that FGF-23 levels can predict the response to therapies aimed to reduce heart failure risk [4].
FGF23 is expressed in the heart and is significantly elevated in heart failure
Recent studies indicate that FGF23 is also expressed in the heart [5]. It is significantly enhanced in clinical and experimental settings of cardiac remodeling and heart failure independent of renal function [6, 10]. Secreted by cardiac myocytes, FGF23 can stimulate pro-fibrotic factors in myocytes to induce fibrosis-related pathways in fibroblasts and consequently cardiac fibrosis. While acting on cardiac myocytes, FGF23 directly induces pro-hypertrophic genes and promotes the progression of LVH (left ventricular hypertrophy) in an autocrine and paracrine fashion. Thus, enhanced FGF23 may promote cardiac injury in various clinical settings by endocrine and paracrine/autocrine mechanisms [7].
FGF23 measurement for prognosis and risk assessment in heart failure
Several large-scale prospective studies show a linear correlation between FGF23 levels and mortality risk, particularly because of LVH and systolic heart insufficiency (heart failure with reduced ejection fraction, HFREF) [2,8]. This clinically evident association between HFREF and FGF23, is likely explained by FGF23 ‘s direct cardiotoxic effects on cardiomyocytes.
Besides the known risk markers in HFREF patients such as serum sodium and BNP, the measurement of FGF23 can thus be of considerable use for risk stratification of individual patients. Of special relevance is the growing evidence that FGF23 levels can predict the response to a therapy with a blocker of the renin-angiotensin-aldosterone system [9].
Cardiovascular risk assessment under ACE therapy
In the PEACE Study (Prevention of Events With Angiotensin-Converting Enzyme) FGF23 was determined in 3,627 patients with stable ischemic heart disease (SIHD) [4]. Increased FGF23 levels correlated, with mortality rate and heart failure, but also identified those patients who benefitted significantly from treatment with ACE inhibitor. This effect was independent of renal function. These results indicate that FGF23 may become an attractive tool for individualized HFREF therapy. Patients with cardiorenal syndrome (combined heart and kidney failure) may benefit from FGF23 determination for estimation of individual risk and initiation of individualized treatment.
FGF23 and therapy monitoring
Patients with kidney disease show elevated serum concentrations of FGF23, associated with cardiovascular and all-cause mortality. A therapeutic approach to reduce increased FGF23 levels is the administration of (calcium-free) phosphatebinders (calcimimetics). The „EVOLVE“ study (2,985 patients receiving hemodialysis with secondary Hyperparathyroidism), demonstrated that treatment-induced reductions in serum FGF23 were associated with lower rates of cardiovascular death and major cardiovascular events. Among patients randomized to cinacalcet, a ≥30% reduction in serum FGF23 between baseline and week 20 was associated with a reduction in the relative hazard of the clinically relevant end point, cardiovascular mortality, sudden cardiac death, and heart failure [9].
Further studies on FGF23
Clearly more experimental and clinical studies are required to justify integrating routine measurement of FGF23 as risk marker for heart failure or to guide treatment. However, it is one of the few promising biomarkers that has high potential to ascertain the effect of FGF23 specific therapeutic interventions on clinically relevant endpoints [10].
Literature
[1] Hu MG, Shiizaki K, Kuro-o M, Moe OW. Fibroblast Growth Factor 23 and Klotho: Physiology and Pathophysiology of an Endocrine Network of Mineral Metabolism. Annu Rev Physiol. 2013;75:503-33.
[2] Brandenburg VM, Kleber ME, Vervloet MG, Tomaschitz A, Pilz S, Stojakovic T, Delgado G, Grammer TB, Marx N, März W, Scharnagl H. Fibroblast growth factor 23(FGF23) and mortality: the Ludwigshafen Risk and Cardiovascular Health Study. Atherosclerosis. 2014 Nov;237(1):53-9.
[3] Olauson H, Vervloet MG, Cozzolino M, Massy ZA, Ureña Torres P, Larsson TE. New insights into the FGF23-Klotho axis. Semin Nephrol. 2014 Nov;34(6):586-97.
[4] Udell JA, Morrow DA, Jarolim P, Sloan S, Hoffman EB, O’Donnell TF, Vora AN,Omland T, Solomon SD, Pfeffer MA, Braunwald E, Sabatine MS. Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. J Am Coll Cardiol. 2014 Jun 10;63(22):2421-8
[5] Itoh N, Ohta H, Nakayama Y, Konishi M. Roles of FGF signals in heart development, health, and disease. Front Cell Dev Biol (2016) 4:110. doi:10.3389/fcell.2016.00110.
[6] Andrukhova O, Slavic S, Odorfer KI, Erben RG. Experimental myocardial infarction upregulates circulating fibroblast growth factor-23. J Bone Miner Res (2015) 30:1831–9. doi:10.1002/jbmr.2527.
[7] Leifheit-Nestler M and Haffner D. Paracrine effects of FGF23 on the Heart. Frontiers in Endocrinology | www.frontiersin.org May 2018 | Volume 9 | Article 278.
[8] Almahmoud MF, Soliman EZ, Bertoni AG, Kestenbaum B, Katz R, Lima JAC, Ouyang P, Miller PE, Michos ED, Herrington DM; Fibroblast Growth Factor-23 and Heart Failure With Reduced Versus Preserved Ejection Fraction: MESA. J Am Heart Assoc. 2018 Sep 18;7(18):e008334.
[9] Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drüeke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J; For the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators. Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation. 2015 July;132(1):27-39
[10] Vervloet M; Renal and Extrarenal Effects of Fibroblast Growth Factor 23. Nature Reviews. Nephrology 15, Nr. 2 (Februar 2019): 109–20.
Read more on our fully validated and CE marked FGF-23 (intact) ELISA and FGF-23 (C-terminal) multi-matrix ELISA for IVD use.
Features and Benefits
- RELIABLE and FULLY VALIDATED for plasma samples – according to ICH Q2
- FAST ONE-STEP ELISA – only 3.5 h total incubation time
- PLASMA-BASED STANDARDS and CONTROLS INCLUDED – for biologically reliable data
- CHARACTERIZED MONOCLONAL ANTIBODIES – high specificity and sensitivity guaranteed
- COMPARABLE RESULTS – correlates with existing methods
The new intact FGF23 ELISA was mentioned in the most recent Biocompare newsletter as a featured product. Check out the drug discovery and development newsletter to learn more.
FGF23 (intact) human ELISA
Features and Benefits
• RELIABLE and FULLY VALIDATED for plasma samples – according to ICH Q2
• SERUM, URINE and CC SUPERNATANT are compatible with this ELISA
• FAST ONE-STEP ELISA – only 3.5 h total incubation time
• PLASMA BASED STANDARDS and CONTROLS INCLUDED – for biologically reliable data
• CHARACTERIZED MONOCLONAL ANTIBODIES – high specificity and sensitivity guaranteed
• GOOD CORRELATION with existing ELISA methods
Why FGF23 ELISA from Biomedica?
√ Proprietary products – developed and manufactured in our European facilities
√ Excellent stability in all matrices after sample collection
√ CE registration in progress
Please click below for:
– Assay Validation Data
– Instruction For Use
– Biomedica FGF23 Info Leaflet
– Product Website
Related Product:
FGF23 (C-terminal) ELISA
|
||
|
||